Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, double-blinded, randomized, placebo-controlled phase 1/2a study to assess safety, tolerability, systemic exposure, and preliminary efficacy of single intraarticular injections of 3 dose levels of SYN321 and placebo in patients with symptomatic knee osteoarthritis.

Next Previous
Trial Profile

A prospective, double-blinded, randomized, placebo-controlled phase 1/2a study to assess safety, tolerability, systemic exposure, and preliminary efficacy of single intraarticular injections of 3 dose levels of SYN321 and placebo in patients with symptomatic knee osteoarthritis.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 06 Mar 2026 Status changed from active, no longer recruiting to completed.
  • 09 Jan 2026 According to a Synartro media release, Unblinding of the study is planned for the second week of March 2026, after which analyses of safety, tolerability, and pharmacokinetic (PK) data will be performed.
  • 09 Jan 2026 According to a Synartro media release, The study was initiated in August 2025 following approval from the Swedish Medical Products Agency (MPA) and the Swedish Ethical Review Authority. The study has enrolled a total of 35 participants with knee osteoarthritis. Cohorts 1-3 have completed the study in accordance with the protocol. Cohort 4 is ongoing, with follow-up assessments conducted at weeks 4 and 6. Last Patient Last Visit (LPLV) is scheduled for the first week of February 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top